Tags

Type your tag names separated by a space and hit enter

The potential of PDE4 inhibitors in respiratory disease.

Abstract

Glucocorticosteroids remain the gold standard therapy for the prophylactic treatment of asthma. Concerns regarding its long-term use particularly in young children has provided an impetus for discovering novel anti-inflammatory molecules with high tolerability and clinical efficacy. Whilst for chronic obstructive pulmonary disease (COPD), there exist no pharmacological treatment for the prevention of decline in lung function. Targeting phosphodiesterase (PDE)4 is one example of this approach and inhibitors of this enzyme are the most advanced drug class in the respiratory pipeline. A number of potent PDE4 inhibitors have undergone clinical trials with moderate success. Tolerability and clinical efficacy issues have dampened enthusiasm in this area. However, with the prospect of newer potent and side effect free inhibitors on the horizon give this area guarded optimism. This review will summarise the most recent information concerning the effectiveness of PDE4 inhibitors as novel anti-inflammatory agents for the treatment of respiratory diseases.

Authors+Show Affiliations

The Sackler Institute of Pulmonary Pharmacology, Hodgkin Building, GKT School of Biomedical Science, Kings College London, SE1 1UL, UK. domenico.spina@kcl.ac.uk

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15379590

Citation

Spina, Domenico. "The Potential of PDE4 Inhibitors in Respiratory Disease." Current Drug Targets. Inflammation and Allergy, vol. 3, no. 3, 2004, pp. 231-6.
Spina D. The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy. 2004;3(3):231-6.
Spina, D. (2004). The potential of PDE4 inhibitors in respiratory disease. Current Drug Targets. Inflammation and Allergy, 3(3), pp. 231-6.
Spina D. The Potential of PDE4 Inhibitors in Respiratory Disease. Curr Drug Targets Inflamm Allergy. 2004;3(3):231-6. PubMed PMID: 15379590.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The potential of PDE4 inhibitors in respiratory disease. A1 - Spina,Domenico, PY - 2004/9/24/pubmed PY - 2004/12/29/medline PY - 2004/9/24/entrez SP - 231 EP - 6 JF - Current drug targets. Inflammation and allergy JO - Curr Drug Targets Inflamm Allergy VL - 3 IS - 3 N2 - Glucocorticosteroids remain the gold standard therapy for the prophylactic treatment of asthma. Concerns regarding its long-term use particularly in young children has provided an impetus for discovering novel anti-inflammatory molecules with high tolerability and clinical efficacy. Whilst for chronic obstructive pulmonary disease (COPD), there exist no pharmacological treatment for the prevention of decline in lung function. Targeting phosphodiesterase (PDE)4 is one example of this approach and inhibitors of this enzyme are the most advanced drug class in the respiratory pipeline. A number of potent PDE4 inhibitors have undergone clinical trials with moderate success. Tolerability and clinical efficacy issues have dampened enthusiasm in this area. However, with the prospect of newer potent and side effect free inhibitors on the horizon give this area guarded optimism. This review will summarise the most recent information concerning the effectiveness of PDE4 inhibitors as novel anti-inflammatory agents for the treatment of respiratory diseases. SN - 1568-010X UR - https://www.unboundmedicine.com/medline/citation/15379590/The_potential_of_PDE4_inhibitors_in_respiratory_disease_ L2 - http://www.eurekaselect.com/91185/article DB - PRIME DP - Unbound Medicine ER -